What We Learned When a Major Type 1 Diabetes Trial Didn't Work as Expected

On March 27, 2026, Diamyd Medical released interim results from DIAGNODE-3, a Phase 3 clinical trial funded by Breakthrough T1D. The trial was designed to test whether Diamyd could slow or halt Type 1 diabetes by preserving the body's ability to produce insulin—measured by a marker called C-peptide. Among the first 174 of 321 total participants analyzed, the therapy showed no measurable preservation of insulin production.

The result was surprising because earlier phases of the DIAGNODE trial had shown positive signs. This shift underscores a critical lesson in drug development: what works in smaller, earlier trials doesn't always translate to larger, more rigorous Phase 3 studies.

Phase 3 clinical trials are the final major hurdle before a therapy can be discussed with regulatory agencies for potential approval. These trials involve many more participants and stricter protocols than earlier trial phases, making them the most realistic test of whether a drug actually works in a diverse population.

While DIAGNODE-3 did not meet its primary goal, completing Phase 3 research—even with disappointing results—provides the kind of rigorous evidence that shapes the future direction of the field.

Breakthrough T1D emphasized that this outcome, though not what researchers hoped for, offers critical insights into how immune therapies work in Type 1 diabetes. The complexity of the disease means that approaches that seem promising in early testing may need refinement or may work better in specific patient subgroups.

Data from trials that don't meet their primary endpoint can reveal important details about dosing, patient selection, timing, and the underlying biology of the disease. Researchers are now analyzing the full DIAGNODE-3 dataset to extract these learnings.

The organization has reaffirmed its commitment to supporting the development of emerging disease-modifying therapies—both immune-based approaches like Diamyd and beta cell therapies designed to repair or replace damaged insulin-producing cells.

The goal of disease-modifying therapies is ambitious: to slow, halt, prevent, or even reverse Type 1 diabetes. DIAGNODE-3's results remind us that this work is complex and that each setback contributes to better-designed studies and more targeted treatments in the future.

The Type 1 diabetes research community continues to pursue multiple therapeutic strategies in clinical trials. This diversity of approaches increases the likelihood that effective disease-modifying therapies will eventually reach patients.

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.